Although amorphous solid dispersions (ASDs) successfully increase bioavailability, they can result in high tablet masses. This paper describes work to reduce the tablet mass of an ASD prepared from a low-Tg, rapidly crystallizing compound. Two polymers were strategically combined to prepare a high-drug-loading ASD tablet with a 40% lower tablet mass. The tablet had similar physical stability and in vitro performance as the benchmark and exhibited excellent downstream manufacturability. To learn more, please see our publication.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center